UCB (OTCMKTS:UCBJY) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of UCB (OTCMKTS:UCBJY) from a strong sell rating to a hold rating in a research note released on Monday morning,Zacks.com reports.

Several other research firms have also commented on UCBJY. Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a research report on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

UCB Stock Down 1.2%

Shares of UCBJY opened at $144.63 on Monday. The business’s fifty day moving average price is $143.65 and its 200 day moving average price is $148.03. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. UCB has a 12-month low of $98.24 and a 12-month high of $168.76.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.